Literature DB >> 6627824

Intravenous cyclosporine kinetics in renal failure.

F Follath, M Wenk, S Vozeh, G Thiel, F Brunner, R Loertscher, M Lemaire, K Nussbaumer, W Niederberger, A Wood.   

Abstract

Kinetics of the novel immunosuppressive cyclosporine were determined in four patients with terminal renal failure. After a short intravenous infusion (2.05 to 3.5 mg/kg in 4 hr), blood and plasma concentrations were measured (HPLC and radioimmunoassay [RIA] up to 36 hr. After infusion, concentration curves of the drug were characterized by a rapid initial fall (t 1/2 alpha 0.10 +/- 0.03 hr), followed by a biphasic elimination phase with corresponding t 1/2s of 1.08 +/- 0.25 hr (t 1/2 beta) and 15.8 +/- 8.4 hr (t 1/2 gamma). The volumes of distribution, calculated from whole blood concentrations (HPLC), were 0.140 +/- 0.48 l/kg (volume of the central compartment) and 3.49 +/- 2.65 l/kg (volume of distribution at steady state), whereas systemic clearances were 0.369 +/- 0.08 l/hr/kg. Blood levels measured by RIA exceeded the HPLC values after the fourth hour by up to 100%, indicating the production of cross-reacting cyclosporine metabolites. Plasma concentrations were considerably lower than in whole blood. Elimination of unchanged cyclosporine in patients with renal failure appears to be of the same order as in those with normal kidney function. Modification of the initial dosage regimens is therefore probably not required.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6627824     DOI: 10.1038/clpt.1983.226

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  28 in total

1.  Comparison of methods to calculate cyclosporine A bioavailability from consecutive oral and intravenous doses.

Authors:  M O Karlsson; A Lindberg-Freijs
Journal:  J Pharmacokinet Biopharm       Date:  1990-08

2.  Effect of renal ischemia on plasma levels of FK 506 in rats.

Authors:  M Sakr; G Zetti; J Gavaler; H Farghali; R Venkataramanan; G Carrieri; T Starzl; D Van Thiel
Journal:  Transplant Proc       Date:  1992-02       Impact factor: 1.066

3.  Cyclosporine Monitoring and Pharmacokinetics in Pediatrie Liver Transplant Patients.

Authors:  G Burckart; T Starzl; L Williams; A Sanghvi; C Gartner; R Venkataramanan; B Zitelli; J Malatack; A Urbach; W Diven; R Ptachcinski; B Shaw; S Iwatsuki
Journal:  Transplant Proc       Date:  1985-02       Impact factor: 1.066

4.  Penetration of cyclosporin into synovial fluid in rheumatoid arthritis.

Authors:  A W van Rijthoven; B A Dijkmans; H S Goei Thè; M Boers; A Cats
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 5.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

6.  Saturable binding of cyclosporin A to erythrocytes: estimation of binding parameters in renal transplant patients and implications for bioavailability assessment.

Authors:  B Legg; M Rowland
Journal:  Pharm Res       Date:  1988-02       Impact factor: 4.200

7.  Effect of a stable analogue of prostacyclin on cyclosporine A-induced nephrotoxicity: morphological qualitative and quantitative studies.

Authors:  M Kobayashi; S Takaya; H Koie
Journal:  Transplant Proc       Date:  1988-02       Impact factor: 1.066

8.  Clinical pharmacokinetics of ciclosporin A in bone marrow transplantation patients.

Authors:  P Bertault-Pérès; D Maraninchi; Y Carcassonne; J P Cano; J Barbet
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

9.  Cyclosporine pharmacokinetic profiles in liver, heart, and kidney transplant patients as determined by high-performance liquid chromatography.

Authors:  G J Burckart; R Venkataramanan; R J Ptachcinski; T E Starzl; B P Griffith; T R Hakala; J T Rosenthal; R L Hardesty; S Iwatsuki; J Brady
Journal:  Transplant Proc       Date:  1986-12       Impact factor: 1.066

Review 10.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.